Do everolimus-eluting bioresorbable vascular scaffolds provide acceptable rates of target lesion failure and scaffold thrombosis in patients undergoing percutaneous coronary intervention in routine clinical practice?
While everolimus-eluting bioresorbable vascular scaffolds showed acceptable target lesion failure rates at 6 months in a real-world European registry, the non-negligible rate of early scaffold thrombosis raises safety concerns.
"Real-world" outcomes of BVS showed acceptable rates of TLF at six months, although the rates of early and midterm scaffold thrombosis, mostly clustered within 30 days, were not negligible.
Capodanno et al. (Sun,) studied this question.